Efficacy of Iodine-125 Seed Implantation in Locoregionally Recurrent and Unresectable Breast Cancer: a Retrospective Study

Abstract

The management of locoregionally recurrent and unresectable breast cancer is a therapeutic challenge. This retrospective study aimed to assess the efficacy of 125 I seed implantation brachytherapy as a palliative management in locoregionally recurrent breast cancer. We analyzed 36 locoregionally recurrent and unresectable breast cancers in our hospital between 2012 and 2016. All patients were treated with CT-guided 125 I seed permanent implantation. The dose distribution of 125 I seeds was calculated using a computerized treatment planning system. Complete response, partial response, stable disease, and local tumor control rates were calculated. Long-term efficacy was assessed based on survival rates ranging from 1 to 4 years. The follow-up period ranged from 6 to 53 months. The median local control was 28 months (95% CI: 16.2-39.8 months). The percentage of patients who showed 6-month, 1-year, 2-year, and 3-year local control was 97.2%, 77.8%, 52.8%, and 33.3%, respectively. Median survival time for all patients was 48 months (95% CI: 40.9-55.1 months); 1-year, 2-year, 3-year, and 4-year survival rates were 97.2%, 80.6%, 63.9%, and 46.5%, respectively. Pain relief response rate was 88.9%. No serious complications were detected during the follow-up period. The results of this study demonstrate that 125 I seed implantation could be considered a feasible and promising minimally invasive therapy for locoregionally recurrent and unresectable breast carcinoma.

Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas

“…Moreover, attempts to improve the survival of HGG patients with increased radiation doses have failed [15]. Iodine-125 seeds are emerging as a safe, effective and minimally invasive method applied in various tumors [16][17][18][19][20]. Several studies have proven that iodine-125 implantation could improve the survival of patients with gliomas [5,[8][9][10][21][22][23].…”

A Comprehensive Narrative Review on the Evolving Role of Endoscopic Ultrasound in Focal Solid Liver Lesions Diagnosis and Management

“…In the last several years, iodine-125 (125I) seed brachytherapy has gained popularity in the treatment of several cancers after showing that this treatment was associated with encouraging local control of solid tumors, such as head and neck cancers and prostate cancer [68][69][70][71]. The therapeutic effect of this treatment is achieved via the introduction of iodine-125 radioactive seeds to the tumorous liver tissue, leading to complete destruction.…”

Feasibility of interstitial stepping-source electronic brachytherapy to locally inoperable tumors

“…Inoperable primary or secondary tumors (metastases) are frequently treated with interstitial brachytherapy, which allows for application of high radiation doses to a lesion, with a steep dose fall-off outside of the target and sparing surrounding (healthy) tissue [ 1 , 2 , 3 , 4 ]. Multiple brachytherapy treatment modalities are available, including catheter-based high-dose-rate (HDR) afterloading brachytherapy with 192 Ir sources or permanent implantation with 125 I seeds (PSI), as the most used methods [ 5 ].…”